Immutep Limited (ASX:IMM)

Market Cap	78.11M -80.9%
Revenue (ttm)	7.92M +62.4%
Net Income	-83.92M
EPS	-0.06
Shares Out	1.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,200,127
Open	0.0530
Previous Close	0.0530
Day's Range	0.0530 - 0.0560
52-Week Range	0.0280 - 0.4700
Beta	2.36
Analysts	Hold
Price Target	0.10 (+88.68%)
Earnings Date	May 7, 2026

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 31
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IMM

Financial Performance

In fiscal year 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.